Top Banner
Can Legflow improve treatment of long femoropopliteal lesions: The REFLOW outcomes Dr. Koen Deloose LINC 2020– Leipzig
25

Can Legflow improvetreatment of long femoropopliteal ...

Nov 07, 2021

Download

Documents

dariahiddleston
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Can Legflow improvetreatment of long femoropopliteal ...

Can Legflow improve treatment of long femoropopliteal lesions:The REFLOW outcomes

Dr. Koen DelooseLINC 2020– Leipzig

Page 2: Can Legflow improvetreatment of long femoropopliteal ...

My disclosures

o I do not have any potential conflicts of interest to report

o I have the following potential conflicts of interest to report:

x

ConsultingEmployment in industryStockholder of a healthcare companyOwner of a healthcare companyOther(s)

Page 3: Can Legflow improvetreatment of long femoropopliteal ...

DCB-treatment works… Proof of concepts DCB

Sing

le a

rm

PASSEO 18 LUX

PTX 3µgr/mm²

+ BTHC

P=0.033

PACCOCATH

PTX 3µgr/mm² + Ultravist

P=0.031

IN.PACT

PTX 3,5µgr/m

m² + Urea

P=0.001

CVI

PTXExcipient?

PACCOCATH

PTX 3µgr/mm² + Ultravist

P<0.001

LUTONIX

PTX 2µgr/mm²

+ polysorbate& sorbitol

P=0.016

ADVANCE

PTX 3µgr/mm²

No excipient

P=0.12

Page 4: Can Legflow improvetreatment of long femoropopliteal ...

1-Year Patency Rates of DCB (in ideal circumstances)

Primary Patency (%) 89.50 89.00 87.50 65.20 N.A.

Lesion Length (mm) 70 72 89.4 62.9 80.4

% Bail-out stenting 6 15.4 7.3 2.5 14.5

% CTO 9.4 19.2 25.8 31.2 22.1

% Severe Ca++ 9.4 12.7 8.1 N.A. 11.7

Short lesions

Limited calcification

Page 5: Can Legflow improvetreatment of long femoropopliteal ...

However in “Real Life”…

Severe Ca++ >30%

LL > 10cm

CTO >30%

Page 6: Can Legflow improvetreatment of long femoropopliteal ...

REFLOW study

A study investigating the Efficacy of the LEGFLOW Paclitaxel-Eluting for the treatment of long

femoropopliteal lesions(TASC C&D)

Page 7: Can Legflow improvetreatment of long femoropopliteal ...

Legflow Drug Coated Balloon

Page 8: Can Legflow improvetreatment of long femoropopliteal ...

Legflow Drug Coated Balloon

Page 9: Can Legflow improvetreatment of long femoropopliteal ...

Legflow Drug Coated Balloon

Page 10: Can Legflow improvetreatment of long femoropopliteal ...

Legflow Drug Coated Balloon

Page 11: Can Legflow improvetreatment of long femoropopliteal ...

Study design

• Study Objective:To evaluate the performance of thePeripheral balloon catheter for the treatment of

• Primary Endpoint:, defined as absence of a

hemodynamically significant stenosis on duplex ultrasound (systolicvelocity ratio ≤2.4) at the target lesion and without reintervention.

Page 12: Can Legflow improvetreatment of long femoropopliteal ...

Participating centers

• BELGIUM• M. Bosiers, K. Deloose, J. Callaert - AZ Sint-Blasius, Dendermonde• P. Peeters, J. Verbist, W. Van den Eynde - Imelda Hospital, Bonheiden• L. Maene, R. Beelen - OLV, Aalst• K. Keirse - RZ Heilig Hart, Tienen• J. Hendriks, P. Lauwers – University Hospital Antwerp, Edegem

• GERMANY• G. Torsello – St. Franziskus-Hospital Münster• D. Scheinert – Universitätsklinikum Leipzig

Page 13: Can Legflow improvetreatment of long femoropopliteal ...

Inclusion criteria

Main inclusion criteria

in the femoropopliteal arteries, suitable for endovascular therapy

• Total target lesion length

120 out of 120 patients enrolled (100%)

Page 14: Can Legflow improvetreatment of long femoropopliteal ...

Study overview

1M 6M 12MBaseline

MedicationPhysical examinationRutherfordABI

Color Flow Ultrasound

DischTimeline 24M

Page 15: Can Legflow improvetreatment of long femoropopliteal ...

Patient Demographics

N = 120Male (%) 65.80% (79/120)

Age (min – max) 71.06 (35.05 – 93.16) years

Nicotine abuse (%) 56.67% (68/120)

Hypertension (%) 77.50% (93/120)

Diabetes mellitus (%) 30.00% (36/120)

Renal insufficiency (%) 15.00% (18/120)

Hypercholesterolemia (%) 53.30% (64/120)

Obesity (%) 19.20% (23/120)

13

80

3

24

Rutherford Classification

RF 2 RF 3 RF 4 RF 5

Page 16: Can Legflow improvetreatment of long femoropopliteal ...

Procedural characteristics

N = 120Procedure time (min-max) 52.17 (19-165) minutes

Scopy time (min – max) 7.32 (1.7 – 39.24) minutes*missing information for 2 patients

Contrast (min – max) 88.09 (9 – 195) mL

Cross-over performed (%) 83.33% (100/120)

Inflow Lesion (%) 10.83% (13/120)

Outflow lesion (%) 21.67% (26/120)

Page 17: Can Legflow improvetreatment of long femoropopliteal ...

Lesion CharacteristicsN = 120

Lesion length (min – max) 216.08 (150 – 390) mm

Ref Vessel Diameter (min – max) 5.40 (4.05 – 6.00) mm

Pre-dilatation 64.20% (77/120)

1 DCB (%)

2 DCB’s (%)

3 DCB’s (%)

25.83% (31/120)

57.50% (69/120)

16.67% (20/120)

Post-dilatation (%) 22.50% (27/120)

Bail-out stenting (%) 35.00% (42/120)

Occlusion (%) 45.00% (54/120)

Calcified lesion (%) 67.50% (81/120)

Page 18: Can Legflow improvetreatment of long femoropopliteal ...

Paclitaxel --> mortality?

Page 19: Can Legflow improvetreatment of long femoropopliteal ...

12-month Survival Rate in 120pts

94.70%

Reasons of death:

Hypoglycemic coma (Day 146)Atrial fibrillation, acute renal insufficiency, critical stenosis aortic valve (Day 163)Pneumonia leading to respiratory arrest (Day 301)Hypernatriemia , acute renal insufficiency (Day 318)Urethral Cancer (Day 318)Reason unknown (Day 335)

With Mean lesion lengths of 216mm, 45% CTO’s

67.50% calcified lesions

All included patients could be categorized as “patients at high risk for restenosis”

Page 20: Can Legflow improvetreatment of long femoropopliteal ...

Primary Patency at 12M (120pts) & 24M (70pts)

0

10

20

30

40

50

60

70

80

90

100Primary Patency

0 60 120 180 240 300 360 420 480 540 600 660 720 780Time (Days)

Cumu

lative

Prim

ary Pa

tency

Rate

(%)

Number at risk70 70 67 67 65 62 58 56 54 54 53 50 47 47 46 45 43 42 42 41 40 40 40 38 36 34 10

66.20%(prelim 70 pts)

71.10%(120 pts)

VERY CHALLENGING LESIONS!

Page 21: Can Legflow improvetreatment of long femoropopliteal ...

Freedom from TLR at 12M (120 pts) & 24M (70pts)

0

10

20

30

40

50

60

70

80

90

100Freedom from Target Lesion Revascularization

0 60 120 180 240 300 360 420 480 540 600 660 720 780Time (Days)

Cumu

lative

Free

dom

from

TLR R

ate (%

)

Number at risk70 70 68 68 66 63 60 58 58 56 56 52 52 50 49 48 46 45 45 44 43 43 43 41 40 38 12

79.90%(120 pts)

72.50%(prelim 70 pts)

Page 22: Can Legflow improvetreatment of long femoropopliteal ...

12-Month REFLOW results in perspective (lesions >20cm)

64.8 68.274.5 80.472.5 76.271.1 79.90

10

20

30

40

50

60

70

80

90

100

Primary Patency Freedom from TLR

Primary Patency (%) Freedom from TLR (%)

BMS DES bypass DCB

Prim

ary

pate

ncy

& F

reed

omfr

omTL

R ra

te(%

)

BMS : Durability 200 study DES : ZILVERPASS Zilver PTX results Bypass ZILVERPASS results DCB : REFLOW results

BMS BMS DESDES bypass bypassDCB DCB

Page 23: Can Legflow improvetreatment of long femoropopliteal ...

24-Month REFLOW results in perspective (lesions >20cm)

BMS : Durability 200 study DES : ZILVERPASS Zilver PTX results Bypass ZILVERPASS results DCB : REFLOW results

BMS DESbypass bypassDCB DCB

0 060.2 72.959.9 67.966.2 72.50

10

20

30

40

50

60

70

80

90

100

Primary Patency Freedom from TLR

24M Primary Patency (%) 24M Freedom from TLR (%)

BMS DES bypass DCB

Prim

ary

pate

ncy

& F

reed

omfr

omTL

R ra

te(%

)

BMS DES

DES bypass

bypass

DCB

N/A N/A

DES bypass DCB

Page 24: Can Legflow improvetreatment of long femoropopliteal ...

Clinical Benefit - Rutherford evolution in 70pts

Page 25: Can Legflow improvetreatment of long femoropopliteal ...

Conclusion

• Final 12-month and preliminary 24-month results suggest that theLEGFLOW DCB is a valid and alternative to treatlong, complex and calcified femoropopliteal lesions

• With a 94.70% survival rate at 12-month, the LEGFLOW DCB proves it’s

• Awaiting for final longer-term results (24-month data)